Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Discovery Grants Program - Individual

Université du Québec à Montréal

$33,500.00

NMR study of the interaction of cardiotoxic drugs with ion channels in their membrane environment

EF 2008-09

Résumé
Long QT syndrome (LQTS) is a cardiac muscle abnormality characterized by a prolongation of the repolarization interval between Q and T waves on the electrocardiogram. This syndrome is caused either by congenital or drug-induced disorders of potassium channels localized in the myocardium cell membranes, and can lead to ventricular arrhythmia and sudden cardiac death. A number of prescription medications inducing long QT have been withdrawn from the market over the past decades, and numerous other drugs have failed the regulatory approval for the same reason. Several drugs still available are forced to carry a warning label. These non-antiarrhythmic compounds have diverse chemical structures and belong to different pharmacological classes (antibiotics, antihistamines, etc). Many medications that prolong the QT interval do so at therapeutic doses. Importantly, virtually all cases of drug-induced LQTS are due to the blockade of the heart human ether-a-go-go-related-gene (hERG) potassium transmembrane channel. One of the greatest challenges in drug design, is, thus, the elaboration of active substances that do not or only slightly bind to hERG channels. Our goal is to better understand the drug-induced blockade of hERG potassium channels causing LQTS. At present, little is known of the structure-activity relationship of the channel blockade or the interaction site(s) inside and around (lipid membrane vicinity) the channel. The determination of molecular characteristics that dictate drug-hERG channel interactions and the location of the binding site(s), using solid-state nuclear magnetic resonance (SS-NMR) and complementary biophysical techniques, could improve our knowledge of drug action and help in predicting their toxicity.
Programme
Discovery Grants Program - Individual
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
326750-2007
Name nom
Marcotte, Isabelle
Department département
Chimie
Organization id
57
Institution établissement
Université du Québec à Montréal
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2008
Competition year année de concours
2007
Award amount
33500
Program id
RGPIN
Program nane en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
26
Committee name en
Anal. & Phys. Chemistry
Committee name fr
Chimie analytique et physique
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
3404
Research subject group en
Physical chemistry
Research subject group fr
Chimie physique
Research subject en
Biophysical chemistry
Research subject fr
Chimie biophysique
Partie
2
Nb partie
3
Application title
NMR study of the interaction of cardiotoxic drugs with ion channels in their membrane environment
Keyword
NA
Application summary
Long QT syndrome (LQTS) is a cardiac muscle abnormality characterized by a prolongation of the repolarization interval between Q and T waves on the electrocardiogram. This syndrome is caused either by congenital or drug-induced disorders of potassium channels localized in the myocardium cell membranes, and can lead to ventricular arrhythmia and sudden cardiac death. A number of prescription medications inducing long QT have been withdrawn from the market over the past decades, and numerous other drugs have failed the regulatory approval for the same reason. Several drugs still available are forced to carry a warning label. These non-antiarrhythmic compounds have diverse chemical structures and belong to different pharmacological classes (antibiotics, antihistamines, etc). Many medications that prolong the QT interval do so at therapeutic doses. Importantly, virtually all cases of drug-induced LQTS are due to the blockade of the heart human ether-a-go-go-related-gene (hERG) potassium transmembrane channel. One of the greatest challenges in drug design, is, thus, the elaboration of active substances that do not or only slightly bind to hERG channels. Our goal is to better understand the drug-induced blockade of hERG potassium channels causing LQTS. At present, little is known of the structure-activity relationship of the channel blockade or the interaction site(s) inside and around (lipid membrane vicinity) the channel. The determination of molecular characteristics that dictate drug-hERG channel interactions and the location of the binding site(s), using solid-state nuclear magnetic resonance (SS-NMR) and complementary biophysical techniques, could improve our knowledge of drug action and help in predicting their toxicity.